Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gastroenterology Endpoints To Get Four-Day Series Of FDA Workshops

This article was originally published in The Pink Sheet Daily

Executive Summary

One day each will be devoted to eosinophilic esophagitis, pediatric and adult inflammatory bowel disease, and parenteral nutrition-associated liver disease, Sept. 19, 20, 21 and 24, in that order.

You may also be interested in...



Gastroenterology Endpoints For IBD Drugs Once Again In FDA Spotlight

FDA is holding another workshop to discuss selection of endpoints in development of drugs to treat pediatric and adult inflammatory bowel diseases; the agency held four gastroenterology workshops last year.

Organize PDUFA V Patient-Focused Meetings Around Disease Clusters, Advocates Say

Patient groups urge FDA not to limit 20 meetings over the next five years to specific diseases, as the agency has proposed, but instead to take a broader view on diseases based upon similar characteristics, quality-of-life burden and available treatment options.

FDA Guidance On Peripheral Neuropathy Drugs In The Works

The agency is holding a public workshop to discuss therapeutic targets and clinical trial design for disease-modifying agents to treat peripheral neuropathy; many products in recent development have faced challenges.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel